Bioventus (NYSE:BVS) Releases FY 2025 Earnings Guidance

Bioventus (NYSE:BVS) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 0.640-0.680 for the period, compared to the consensus earnings per share estimate of 0.550. The company issued revenue guidance of $560.0 million-$570.0 million, compared to the consensus revenue estimate of $554.8 million.

Wall Street Analyst Weigh In

Separately, JPMorgan Chase & Co. raised shares of Bioventus from an “underweight” rating to a “neutral” rating and upped their price target for the company from $12.00 to $13.00 in a report on Tuesday, December 17th.

Bioventus Stock Performance

Shares of NYSE BVS opened at $10.37 on Tuesday. The company’s fifty day moving average price is $10.12 and its 200 day moving average price is $11.01. The company has a market capitalization of $841.58 million, a PE ratio of -17.00 and a beta of 0.86. Bioventus has a 1 year low of $3.90 and a 1 year high of $14.38. The company has a debt-to-equity ratio of 1.85, a quick ratio of 0.99 and a current ratio of 1.41.

Insider Activity at Bioventus

In other Bioventus news, SVP Anthony D’adamio sold 4,380 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $10.19, for a total transaction of $44,632.20. Following the completion of the transaction, the senior vice president now owns 118,178 shares of the company’s stock, valued at $1,204,233.82. This represents a 3.57 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Katrina J. Church sold 2,535 shares of Bioventus stock in a transaction that occurred on Monday, December 23rd. The stock was sold at an average price of $10.53, for a total value of $26,693.55. Following the completion of the sale, the senior vice president now directly owns 47,264 shares in the company, valued at $497,689.92. This represents a 5.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 52,932 shares of company stock worth $512,511 in the last 90 days. Corporate insiders own 32.90% of the company’s stock.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.